Pathwork Diagnostics

Pathwork was developing microarray-based diagnostics to advance cancer care. The company's FDA-cleared Pathwork® Tissue of Origin Test helped to determine the origin of hard-to-identify tumours so that physicians and oncologists could optimise therapies. The company was acquired by Response Genetics in August 2013.